top of page
The only magnesium in orthopedics.
Mg OsteoCrete® & Mg OsteoInject® · Bone Solutions, Inc.
A bone solution that fills the void, bonds to bone and hardware, and then resorbs — remodeling into the patient's own bone on a documented timeline.
Every other bone void filler on the market is built on calcium — calcium sulfate, calcium phosphate, hydroxyapatite. Mg OsteoCrete and Mg OsteoInject are built on magnesium, and that single difference changes what happens after the case is closed.
Magnesium is not a foreign material in bone. Roughly 60% of the body's magnesium resides in the skeleton, where it participates directly in bone formation and in the regulation of calcium itself. A magnesium-based cement is therefore not an inert space-filler placed and left behind — it is a material the body recognizes, integrates, and ultimately replaces.
This is a complete magnesium platform, not a single product. One chemistry, three working viscosities — so the material meets the defect rather than the defect accommodating the material.
Mg OsteoCrete — the workhorse of the line, and the form most often reached for. A single kit gives you two consistencies: a packable putty for open defects, voids, and augmentation of hardware fixation, and a flowable paste that delivers through a cannula when the defect can't be fully exposed.
Mg OsteoInject — the third viscosity, and the lowest. The same magnesium chemistry taken flowable enough for percutaneous work: it mixes in about 30 seconds, injects through an 11-gauge needle, is drillable, radiopaque, and sets in roughly two minutes.
What it is
How it Works
It fills — at whatever consistency the defect demands.
An open calcaneal void and a subchondral lesion reached through a needle are not the same problem, and magnesium meets both. OsteoCrete packs as a putty into a defect you can see and work, or runs as a flowable paste through a cannula into one you can't fully expose. OsteoInject goes further still — low enough in viscosity to pass an 11-gauge needle under fluoroscopic guidance, interdigitating with trabecular bone rather than simply occupying a cavity, reaching subchondral lesions, cysts, and insufficiency fractures without opening the joint.
It cures — and it holds under load.
Once set, the material bonds to bone and to metal. Bench data show approximately 30% greater screw-anchoring strength than PMMA,* with an adhesive, cohesive set rather than a brittle ceramic one. In the foot and ankle, where every void sits beneath body weight, this matters: the construct has to hold while biology catches up.
It resorbs — and this is the part that separates it.
Calcium sulfate products dissolve quickly, sometimes faster than bone can form, and carry a documented history of serous wound drainage. Hydroxyapatite cements sit at the opposite extreme — they set hard and then largely stay, radiographically persistent for years, with published human retrievals showing material still unresorbed years after implantation.
Magnesium does neither. It resorbs on a predictable, matched timeline, and serial human radiographs published over a full twelve months document the material giving way to remodeled bone rather than simply disappearing or persisting.†
And it is non-reactive.
The set reaction is low-exotherm — no thermal insult to surrounding bone — and the ion released as the material resorbs is one the skeleton already uses every day.
Foot & ankle — calcaneal and lateral malleolar fractures, osteotomy and fusion sites, subchondral defects and cysts of the talus, insufficiency fractures across the midfoot and forefoot.
Bone marrow edema & subchondral pathology — OsteoInject delivered percutaneously into subchondral bone marrow lesions, where the goal is to support the failing trabecular bone and then leave healed bone behind.
Trauma & fixation augmentation — filling metaphyseal voids and augmenting hardware purchase in osteoporotic and comminuted bone. Cleared as an adjunct to hardware fixation.
Upper extremity — proximal humerus fracture fixation, where a published case series using an OsteoCrete augmentation protocol reported 82.3% radiographic healing with an 11.8% reoperation rate.‡
Pediatric bone cysts — as of October 2025, both Mg OsteoCrete and Mg OsteoInject are FDA-cleared for pediatric patients aged six and older. The published ScleroGraft™ technique — chemical curettage with doxycycline followed by OsteoInject delivered through a needle — offers an outpatient, needle-only approach to unicameral bone cysts.§
Where it's Used
Indications
IndicationsBone voids and gaps not intrinsic to the stability of the bony structure; insufficiency fractures and microfractures; adjunct to hardware fixation to support bone fragments during the surgical procedure. Pediatric patients aged six and older. See the manufacturer's IFU for complete indications, contraindications, warnings, and technique.
bottom of page